Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-31

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate prevalence of splenomegally in patients with isolated thrombocytopenia.

Asess effect of splenomegally in clinical picture ,Complication, treatment response and disease outcome To explain possible causes of splenomegally in patients with isolated thrombocytopenia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura

NCT04056507

Immune Thrombocytopenic Purpura Splenectomy; Status

COMPLETED

Bleeding Prediction in Thrombocytopenia

NCT02306044

Thrombocytopenia

COMPLETED

The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia

NCT01869049

Immune Thrombocytopenia

WITHDRAWN

Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.

NCT04070599

Immune Thrombocytopenic Purpura Autoimmune Thrombocytopenia Thrombopenia

COMPLETED PHASE3

Diagnostic of Chronic Thrombocytopenia

NCT04071496

Congenital Thrombocytopenia Chronic Idiopathic Thrombocytopenic Purpura

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Immune Thrombocytopenic Purpura Amegakaryocytic Aplasia Unilineage Myelodysplastic Syndrome ( Megakaryocyte Dysplasia) Lymphoproliferative Disorder With Secondary ITP Autoimmune Diseases With Secondary ITP

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1a patients with isolated thrombocytopenia and splenomegaly

Group 1b patients with isolated thrombocytopenia without splenomegaly.

No interventions assigned to this group

Group 1b patients with isolated thrombocytopenia without splenomegaly.

No interventions assigned to this group

Group 2 healthy volunteers.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients more than 18 years admitted with isolated thrombocytopenia due to primary Immune thrombocytopenic purpura amegakaryocytic aplasia Unilineage myelodysplastic syndrome ( megakaryocyte dysplasia) lymphoproliferative disorder with secondary ITP autoimmune diseases with secondary ITP Willingness to participate in the study Admitted patients or those who follow at hematology outpatients clinic

Exclusion Criteria

EDTA induced pseudothrombocytopenia Platelet satellitism Drug induced thrombocytopenia Heparin induced thrombocytopenia / thrombosis syndrome post transfusion purpura Disseminated intravascular coagulopathy patients less than 18 years old patients with bicytopenia or pancytopenia Pregnancy

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes